An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...

New antibody AHA-1031 shows potential in treating non small cell lung cancer resistant to immunotherapy, offering new hope.

Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced today that it has received a Notice of Allowance ...

The AVAR1901CN patent focuses on innovative technology designed to enhance the expansion, manufacturing, survival, and efficacy of CAR-T and CAR-Natural Killer (NK) cells. Its key features include ...

Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced ...

“We’re excited about the potential of this new strategy,” said Dr. Xiaowei “George” Xu, a Penn Pathology and Laboratory ... from natural killer (NK) cells, a type of immune cell ...

1Masonic Cancer Center, Minneapolis, Minnesota. 6Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota. 7Department of ...

Researchers at The Wistar Institute's HIV Cure and Viral Diseases Center have successfully identified a new approach using ...

Biomissile Pharmaceuticals Co. Ltd. is developing multispecific antibodies that overcome resistance associated with antibody-drug conjugates via its next-generation natural killer (NK) cell engagers.

Within the immune system, interleukin-15 (IL-15) plays a relevant role by boosting the number of cytotoxic T cells and NK cells, the major drivers of anticancer immune response. Researchers from Sotio ...